Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

A Study on the Pharmacokinetics and Safety of GST-HG141 Tablets in Participants With Hepatic Impairment and Normal Liver Function

13. listopadu 2026 aktualizováno: Fujian Akeylink Biotechnology Co., Ltd.

This is a multicenter, non-randomized, open-label, parallel-group, single-dose study designed to evaluate the pharmacokinetic profiles and safety of GST-HG141 tablets in participants with hepatic impairment.

Přehled studie

Postavení

Nábor

Intervence / Léčba

Typ studie

Intervenční

Zápis (Odhadovaný)

24

Fáze

  • Fáze 1

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní kontakt

Studijní místa

    • Jiangsu
      • Suzhou, Jiangsu, Čína
        • Nábor
        • The Second Affiliated Hospital of Soochow University
        • Kontakt:

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

18 let až 65 let (Dospělý, Starší dospělý)

Přijímá zdravé dobrovolníky

Ano

Pohlaví způsobilá ke studiu

Všechno

Popis

Inclusion Criteria:

Participants must meet all of the following inclusion criteria to be enrolled in this study.

  1. Participants aged 18 to 65 years (inclusive, as of the date of signing the informed consent form), male or female;

  2. Body weight at screening: ≥ 50 kg for males and ≥ 45 kg for females; body mass index (BMI) ranging from 18.0 to 30.0 kg/m² (inclusive of 18.0 and 30.0);

  3. Voluntarily agree to participate and provide written informed consent, and comply with the study treatment plan and visit schedule;

  4. Participants (including their partners) agree to have no childbearing plan and voluntarily use effective contraceptive measures from screening until 3 months after administration of the investigational product, and have no plan to donate sperm or oocytes;

  5. Estimated glomerular filtration rate (eGFR, calculated by the CKD-EPI 2021 equation) ≥ 60 mL/(min·1.73 m²).

    Participants with normal hepatic function must additionally meet all of the following criteria:

  6. Demographic and baseline means of participants in the normal hepatic function group (Group C) at screening must satisfy the following matching criteria:

    1. Body weight matched with the hepatic impairment groups (Group A + Group B), with a mean difference within ±10 kg;
    2. Age matched with the hepatic impairment groups (Group A + Group B), with a mean difference within ±10 years;
    3. Gender distribution matched with the hepatic impairment groups (Group A + Group B), with a difference in number within ±1 subject.

    Participants with hepatic impairment must additionally meet all of the following criteria:

  7. Previously diagnosed with liver cirrhosis via liver biopsy or other medical imaging techniques (including laparoscopy, computed tomography [CT], magnetic resonance imaging [MRI], or ultrasound), with a disease duration of ≥6 months and stable disease status (judged by the investigator based on the participant's condition) for ≥4 weeks; without albumin administration within 14 days, classified as Child-Pugh Class A or B based on Child-Pugh score (grade of encephalopathy, ascites, serum albumin, serum bilirubin, and seconds of prolonged prothrombin time);

  8. Except for hepatic insufficiency and its complications, the investigator judges the participant's general medical condition to be acceptable based on medical history inquiry, physical examination, vital signs, laboratory tests (routine blood test, blood biochemistry, coagulation function, routine urine test), AFP, 12-lead ECG, chest anteroposterior radiograph, B-ultrasound, etc.;

  9. No medication for at least 14 days prior to dosing of the investigational product, or on a stable medication regimen for the treatment of hepatic impairment, its complications, and other concomitant diseases, with no changes to medication (including drug type, dosage, or frequency of administration) within 14 days prior to dosing of the investigational product.

  10. Participants with chronic hepatitis B shall have stable disease, with no evidence of acute hepatitis exacerbation or acute hepatic decompensation; and any antiviral therapy must have been administered stably for at least 4 weeks prior to screening.

Exclusion Criteria:

For all participants:

  1. Participants with allergic constitution, including those with a known history of allergy to two or more types of foods and drugs, or a known previous allergic reaction to the active ingredients or excipients of GST-HG141 Tablets;

  2. Participants who have undergone major surgery (excluding diagnostic surgery) within 6 months prior to screening, plan to receive surgery during the study period, or have received surgery judged by the investigator to affect safety evaluation or drug absorption, distribution, metabolism and excretion;

  3. Participants who develop an acute disease within 2 weeks before dosing, which is judged by the investigator to affect safety evaluation or drug absorption, distribution, metabolism and excretion;

  4. Participants with a history of infectious diseases within 4 weeks prior to screening (conditions that may significantly affect the safety evaluation of participants as assessed by the investigator);

  5. Participants who have received vaccination within 30 days prior to screening or plan to receive vaccination during the study period;

  6. Participants with positive human immunodeficiency virus (HIV) or syphilis test results at screening;

  7. Participants with frequent alcohol consumption within 3 months prior to screening, defined as an average weekly alcohol intake exceeding 14 alcohol units (1 unit = 360 mL beer with 5% alcohol content, or 45 mL spirits with 40% alcohol content, or 150 mL wine with 12% alcohol content); those who cannot refrain from all alcoholic products during the trial; or those with a positive alcohol breath test;

  8. Participants with an average daily cigarette consumption of ≥ 5 cigarettes within 3 months prior to screening, or those who refuse to stop using all tobacco products during the trial;

  9. Participants who consume caffeine-containing foods or beverages (e.g., coffee, tea, chocolate, caffeinated carbonated drinks, cola), grapefruit, grapefruit juice or poppy-containing foods within 24 hours before dosing and cannot discontinue such intake during the trial; those who cannot avoid strenuous exercise from 24 hours before dosing throughout the trial period;

  10. Participants with difficulty in swallowing tablets, or those with special dietary restrictions who cannot accept unified meals;

  11. Participants with difficulty in venous blood collection or a history of needle or blood phobia;

  12. Participants who have donated blood or had a total blood loss of ≥ 400 mL within 3 months prior to screening, or plan to donate blood during the study period and within 1 month after the final follow-up;

  13. Participants with a history of gastrointestinal diseases (including active conditions) affecting drug absorption from 1 year prior to screening up to enrollment, including those with severe (assessed by the investigator) or active upper gastrointestinal diseases, active gastrointestinal bleeding, or a history of gastrointestinal surgery.

  14. Participants with a history of drug abuse (including non-medical use of narcotic drugs and psychotropic substances) within 1 year prior to screening to enrollment, or with positive urine drug screening results (including morphine, methamphetamine, ketamine, MDMA, tetrahydrocannabinolic acid, etc.);

  15. Participants deemed unsuitable for participation by the investigator, or those who request to withdraw from the trial on their own initiative;

  16. Participants diagnosed with hepatitis B or hepatitis D.

    For female participants (in addition to the above criteria, those meeting any of the following shall also be excluded):

  17. Participants who used oral contraceptives within 30 days prior to screening to enrollment;

  18. Participants who received long-acting estrogen or progestogen injections (including progestogen-only intrauterine devices) or implantable contraceptives within 6 months prior to screening to enrollment;

  19. Participants who had unprotected sexual intercourse with their partners within 14 days prior to screening to enrollment;

  20. Participants with a positive pregnancy test;

  21. Pregnant or lactating women.

    For participants with hepatic impairment (excluded if meeting any of the following criteria):

  22. Cirrhosis patients with any of the following conditions deemed inappropriate by the investigator: drug-induced liver injury, history of liver transplantation, liver failure, hepatocellular carcinoma (excluding Barcelona Clinic Liver Cancer Stage 0 or patients with curative treatment outcomes), hepatorenal syndrome, active Grade 3 or 4 hepatic encephalopathy, or complications such as esophagogastric variceal rupture and bleeding occurring within 3 months prior to screening;

  23. Participants with active syphilis (positive treponema pallidum antibody plus positive TRUST/RPR), active hepatitis C (anti-HCV positive with HCV RNA above the normal reference range), or active hepatitis B (HBsAg positive with HBVDNA above the normal reference range) at screening;

  24. Participants with drug-induced liver injury or acute liver injury caused by any other etiology;

  25. Participants with severe ascites and/or pleural effusion (exceptions may be granted for participants with stable physical conditions as judged by the investigator);

  26. Participants with systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥ 100 mmHg at screening (enrollment is permitted if blood pressure is stably controlled with medication for at least one week as assessed by the investigator);

  27. Participants with biliary tract obstruction;

  28. Participants suffering from other severe systemic organ diseases at screening in addition to primary liver diseases, including but not limited to gastrointestinal, respiratory, renal, neurological, hematological, endocrine, neoplastic, immune, psychiatric, cardiovascular and cerebrovascular diseases, and judged by the investigator to be ineligible for this trial;

  29. Participants with any of the following laboratory abnormalities at screening: (a) alanine transaminase (ALT) or aspartate transaminase (AST) > 5×ULN (one repeat test is allowed); (b) serum alpha-fetoprotein (AFP) > 20 ng/mL;

  30. Participants who have taken concomitant medications that may interact with the study drug within 2 weeks before dosing, including inhibitors and inducers of CYP3A4 and P-gp ;

  31. Participants who have used albumin within 1 month prior to screening;

  32. Participants who have participated in any clinical trial within 1 month prior to screening, or are still within 7 half-lives of other investigational drugs at screening (whichever is longer), or plan to participate in other clinical trials during this study.

    For healthy participants (excluded if meeting any of the following criteria):

  33. Participants with clinically significant abnormal findings in vital sign examination, physical examination, clinical laboratory tests (routine blood test, routine urine test, blood biochemistry, coagulation function), infectious disease screening, 12-lead electrocardiogram, abdominal color ultrasound and chest anteroposterior radiograph at screening, as judged by the investigator;

  34. Participants with a history of chronic or severe diseases involving the cardiovascular, hepatic, renal, biliary, respiratory, hematologic and lymphatic, endocrine, immune, psychiatric, neuromuscular, or gastrointestinal systems from 1 year prior to screening up to enrollment, which are judged clinically significant by the investigator.

  35. Participants with clinically significant abnormal electrocardiogram results during the screening period;

  36. Participants who have taken any prescription drugs, over-the-counter drugs, health supplements, vitamins, Chinese herbal medicines and other products within 14 days prior to screening;

  37. Participants who have used other investigational drugs within 3 months prior to screening or plan to participate in other clinical trials during this study.

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

  • Primární účel: Léčba
  • Přidělení: Nerandomizované
  • Intervenční model: Paralelní přiřazení
  • Maskování: Žádné (otevřený štítek)

Zbraně a zásahy

Skupina účastníků / Arm
Intervence / Léčba
Experimentální: Part A

mild hepatic impairment

GST-HG141 will be administered as a single oral dose on the morning of day 1

Experimentální: Part B

moderate hepatic impairment

GST-HG141 will be administered as a single oral dose on the morning of day 1

Experimentální: Part C

healthy participants

GST-HG141 will be administered as a single oral dose on the morning of day 1

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Maximum observed plasma concentration (Cmax) for GST-HG141
Časové okno: up to 6 days

Maximum observed plasma GST-HG141 concentration.

up to 6 days

Sekundární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
AEs
Časové okno: up to 11 days

To evaluate the safety and tolerability of GST-HG141 tablets

up to 11 days

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia (Aktuální)

3. července 2026

Primární dokončení (Odhadovaný)

31. prosince 2026

Dokončení studie (Odhadovaný)

31. ledna 2027

Termíny zápisu do studia

První předloženo

9. listopadu 2026

První předloženo, které splnilo kritéria kontroly kvality

13. listopadu 2026

První zveřejněno (Aktuální)

18. listopadu 2026

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

18. listopadu 2026

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

13. listopadu 2026

Naposledy ověřeno

1. dubna 2026

Více informací

Termíny související s touto studií

Informace o lécích a zařízeních, studijní dokumenty

Studuje lékový produkt regulovaný americkým FDA

Ne

Studuje produkt zařízení regulovaný americkým úřadem FDA

Ne

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .

Předplatit